QUOTE AND NEWS
Motley Fool  Jan 5  Comment 
The blood-cancer-focused biotech isn't out of the woods yet, but it looks like it will finally be allowed to continue an important clinical trial.
newratings.com  Aug 30  Comment 
CANONSBURG (dpa-AFX) - Amgen Inc.'s (AMGN) phase III study of Prolia in patients receiving glucocorticoid therapy has met all primary and secondary endpoints at 12 months. According to the study results, Prolia led to significantly greater...
newratings.com  Jun 7  Comment 
VIENNA (dpa-AFX) - CTI BioPharma Corp. (CTIC) announced long-term safety and efficacy results from the Phase 3 PERSIST-1 trial evaluating pacritinib versus best available therapy, excluding treatment with JAK2 inhibitors, or BAT, in patients with...
newratings.com  Feb 10  Comment 
NEW BRUNSWICK (dpa-AFX) - Axovant Sciences Ltd. (AXON) expects results from a phase II study of Nelotanserin in Lewy body dementia subjects experiencing visual hallucinations in the second half of calendar year 2016. A phase IIb study of RVT-101...
Benzinga  Nov 23  Comment 
CTI BioPharma Corp. (NASDAQ: CTIC) announced the initiation of its rolling new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1...
newratings.com  Nov 23  Comment 
WASHINGTON (dpa-AFX) - CTI BioPharma Corp. (CTIC) Monday announced the presentation of preclinical data demonstrating potential synergistic combination of Pacritinib and an epidermal growth factor receptor or EGFR inhibitor in targeting brain...




 

Thinking about getting a kdlnie? the apple kdlnie blog works an assessment to make a example. Learn about its traits and iphone 6 do a comparison of it together with contesting products. at the New iphone same time check out the Ipods many kdlnie accessories the website lists out for you personally.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki